NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
Read More
Trailing Twelve Months EPS: ($1.40)
2025 EPS Estimate: ($1.30)
2026 EPS Estimate: ($1.72)
- Current Stock Price
- $25.94
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $32.67 (26.0% Upside)
